Caitong International Asset Management’s Annovis Bio ANVS Stock Holding History

Caitong International Asset Management’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11	Buy	6 +4	+200%	+$8	﹤0.01%	2622
2026 Q1	$4	Buy	+2	New	+$5	﹤0.01%	2308
2025 Q3	–	Sell	-1	Closed	-$2	–	1925
2025 Q2	$2	Buy	+1	New	+$2	﹤0.01%	1915
2025 Q1	–	Sell	-79	Closed	-$397	–	2151
2024 Q4	$397	Buy	+79	New	+$572	﹤0.01%	1495

Other funds holding ANVS

FNT

First National Trust Hermitage, Pennsylvania $2.95B AUM 27.19% 1-Year Est. Return

Sherry Group Mountain Home, Arkansas $102M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

WFAG

Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.29B AUM 21.04% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

QWM

Quadcap Wealth Management Frisco, Texas $1.03B AUM 28.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Caitong International Asset Management's ANVS Position: Q2 2026 in Review

Caitong International Asset Management increased its Annovis Bio (ANVS) stake by 200% in Q2 2026, buying an estimated $8 and bringing the position to 6 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #2622.

Caitong International Asset Management first reported a position in ANVS in Q4 2024 and has held it in 4 quarters since. The position peaked at $397 in Q4 2024. 19 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

Caitong International Asset Management held 6 shares of Annovis Bio worth $11 as of Q2 2026.
Caitong International Asset Management bought 4 Annovis Bio shares in Q2 2026, an estimated $8.
Annovis Bio made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2622 holding.
Caitong International Asset Management first reported a position in Annovis Bio in Q4 2024 and has held it in 4 quarters since.
Caitong International Asset Management's Annovis Bio position peaked at $397 in Q4 2024.
19 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.